First National Trust CO Biomarin Pharmaceutical Inc Transaction History

First National Trust CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	SELL	$86.68 - $100.3 $525,454 - $608,018	-6,062 Reduced 63.47%	3,489 $302,000
Q1 2023 Apr 26, 2023	SELL	$87.74 - $117.27 $209,435 - $279,923	-2,387 Reduced 19.99%	9,551 $928,000
Q4 2022 Feb 02, 2023	SELL	$80.93 - $108.63 $786,720 - $1.06 Million	-9,721 Reduced 44.88%	11,938 $1.24 Million
Q3 2022 Nov 02, 2022	SELL	$82.16 - $96.94 $4.92 Million - $5.8 Million	-59,869 Reduced 73.43%	21,659 $1.84 Million
Q2 2022 Aug 03, 2022	SELL	$71.48 - $86.85 $166,619 - $202,447	-2,331 Reduced 2.78%	81,528 $6.76 Million
Q1 2022 May 03, 2022	BUY	$74.28 - $92.69 $510,600 - $637,151	6,874 Added 8.93%	83,859 $6.47 Million
Q4 2021 Feb 03, 2022	BUY	$71.72 - $91.47 $367,851 - $469,149	5,129 Added 7.14%	76,985 $6.8 Million
Q3 2021 Nov 05, 2021	BUY	$74.77 - $85.47 $231,712 - $264,871	3,099 Added 4.51%	71,856 $5.55 Million
Q2 2021 Aug 06, 2021	BUY	$75.51 - $84.79 $1.02 Million - $1.14 Million	13,455 Added 24.33%	68,757 $5.74 Million
Q1 2021 May 06, 2021	BUY	$74.73 - $90.69 $4.13 Million - $5.02 Million	55,302 New	55,302 $4.18 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of First National Trust CO, based on Form 13F filings with the SEC.

Stay updated on First National Trust CO with notifications on news.